FSPKF (Fisher & Paykel Healthcare) EPS without NRI: $0.47 (TTM As of Mar. 2026)


FSPKF Fisher & Paykel Healthcare Corp Ltd FSPKF
90 GF Score
Price $22.52
GF Value $27.43
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare EPS without NRI?

Fisher & Paykel Healthcare FSPKF +9.59% 90 EPS without NRI is $0.47 as of Mar. 2026. GuruFocus rates FSPKF with a GF Score™ of 90/100 and a GF Value™ of $27.43 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 666 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 68.92% on this metric.

Fisher & Paykel Healthcare's earnings per share without non-recurring items for the six months ended in Mar. 2026 was $0.25. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.47.

During the past 12 months, Fisher & Paykel Healthcare's average earnings per share (NRI) Growth Rate was 24.10% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 22.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -3.80% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Fisher & Paykel Healthcare's EPS without NRI or its related term are showing as below:

FSPKF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37   Med: 13   Max: 76.2
Current: 22.6

During the past 13 years, Fisher & Paykel Healthcare's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 76.20% per year. The lowest was -37.00% per year. And the median was 13.00% per year.

FSPKF's 3-Year EPS without NRI Growth Rate is ranked better than
68.92% of 666 companies
in the Medical Devices & Instruments industry
Industry Median: 8.15 vs FSPKF: 22.60

Fisher & Paykel Healthcare's EPS (Diluted) for the six months ended in Mar. 2026 was $0.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.47.

Fisher & Paykel Healthcare's EPS (Basic) for the six months ended in Mar. 2026 was $0.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.47.


Fisher & Paykel Healthcare  (OTCPK:FSPKF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Fisher & Paykel Healthcare EPS without NRI Related Terms


Fisher & Paykel Healthcare EPS without NRI Historical Data

* Premium members only.

The historical data trend for Fisher & Paykel Healthcare's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fisher & Paykel Healthcare EPS without NRI Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.27 0.14 0.37 0.46

Fisher & Paykel Healthcare Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.16 0.22 0.21 0.25

FSPKF vs ISRG, BDX, MDLN: EPS without NRI Comparison

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fisher & Paykel Healthcare PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's PE Ratio without NRI falls into.


FSPKF
90GF Score
Fisher & Paykel Healthcare Corp Ltd FSPKF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fisher & Paykel Healthcare EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.47 mean?
Fisher & Paykel Healthcare (FSPKF) has a EPS without NRI of $0.47 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Fisher & Paykel Healthcare and its competitors. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #207 out of 666 companies in the Medical Devices & Instruments industry, placing it in the top 31.1%.
Is Fisher & Paykel Healthcare's EPS without NRI too high?
Fisher & Paykel Healthcare's current EPS without NRI is $0.47. The Medical Devices & Instruments industry median EPS without NRI is 8.15. Fisher & Paykel Healthcare's value of $0.47 is 94.2% below this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #207 out of 666 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #207 out of 666 companies for EPS without NRI. This puts Fisher & Paykel Healthcare in the upper half of its industry. The industry median EPS without NRI is 8.15. Fisher & Paykel Healthcare's value of $0.47 is 94.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current EPS without NRI of $0.47 is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current EPS without NRI is $0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FSPKF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.43, compared to a current price of $22.52 — trading 17.9% below its estimated fair value. The current EPS without NRI is $0.47 and 94.2% below the Medical Devices & Instruments industry median of 8.15. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FSPKF), the current EPS without NRI is $0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (FSPKF) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of $22.52 is trading 17.9% below its estimated GF Value™ of $27.43. GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.

Key valuation signals for FSPKF:

  • EPS without NRI: $0.47
  • GF Value™: $27.43 vs. price of $22.52 (17.9% below fair value)
  • GF Score™: 90/100 with 2 warning signs
  • Industry Position: 94.2% below the Medical Devices & Instruments median (#207 of 666)

No single metric tells the full story. See the FSPKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fisher & Paykel Healthcare Business Description

Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score

Get the complete analysis for FSPKF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.52
Price
$27.43
GF Value